...
首页> 外文期刊>Pharmacogenetics and genomics >Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms
【24h】

Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms

机译:第二代抗精神病药物氯氮平及其活性代谢产物N-去甲基氯氮平的葡萄糖醛酸化作用。 UGT1A1 A(TA)7TAA和UGT1A4 L48V多态性的潜在重要性

获取原文
获取原文并翻译 | 示例

摘要

Introduction: Clozapine (CLZ) is an FDA approved second-generation antipsychotic for refractory schizophrenia, and glucuronidation is an important pathway in its metabolism. The aim of this study was to fully characterize the CLZ glucuronidation pathway and examine whether polymorphisms in active glucuronidating enzymes could contribute to variability in CLZ metabolism. Methods: Cell lines overexpressing wild-type or variant uridine diphosphate-glucuronosyltransferase (UGT) enzymes were used to determine which UGTs show activity against CLZ and its major active metabolite N-desmethylclozapine (dmCLZ). Human liver microsomes (HLM) were used to compare hepatic glucuronidation activity against the UGT genotype. Results: Several UGTs including 1A1 and 1A4 were active against CLZ; only UGT1A4 showed activity against dmCLZ. UGT1A1 showed a 2.1-fold (P0.0001) higher V max/K M for formation of the CLZ-N +-glucuronide than UGT1A4; UGT1A4 was the only UGT for which CLZ-5-N-glucuronide kinetics could be determined. The UGT1A4 24Pro/48Val variant showed a 5.2-, 2.0-, and 3.4-fold (P0.0001 for all) higher V max/K M for the formation of CLZ-5-N-glucuronide, CLZ-N-glucuronide, and dmCLZ-5-N +-glucuronide, respectively, as compared with that of wild-type UGT1A4 24Pro/48Leu. There was a 37% (P0.05) decrease in the rate of CLZ-N +-glucuronide formation in HLM with the UGT1A1 (*28/*28)/UGT1A4 (*1/*1) genotype, and a 2.2-and 1.8-fold (P0.05 for both) increase in the formation of CLZ-5-N +-glucuronide and CLZ-N-glucuronide in UGT1A1 (*1/*1)/ UGT1A4 (*3/*3) HLM compared with UGT1A1 (*1/*1)/UGT1A4 (*1/*1) HLM. The UGT1A1*28 allele was a significant (P=0.045) predictor of CLZ-N-glucuronide formation; the UGT1A4*3 allele was a significant (P0.0001) predictor of CLZ-5-N +-glucuronide and dmCLZ-glucuronide formation. Conclusion: These data suggest that the UGT1A1*28 and UGT1A4*3 alleles contribute significantly to the interindividual variability in CLZ and dmCLZ metabolism.
机译:简介:氯氮平(CLZ)是FDA批准的用于难治性精神分裂症的第二代抗精神病药,葡萄糖醛酸苷化是其代谢的重要途径。这项研究的目的是全面表征CLZ葡萄糖醛酸化途径,并检查活性葡萄糖醛酸化酶中的多态性是否可能导致CLZ代谢的变异。方法:使用过度表达野生型或变体尿苷二磷酸-葡萄糖醛酸转移酶(UGT)的细胞系来确定哪些UGT对CLZ及其主要活性代谢物N-去甲基氯氮平(dmCLZ)具有活性。使用人肝微粒体(HLM)来比较针对UGT基因型的肝葡萄糖醛酸化活性。结果:包括1A1和1A4在内的几种UGT对CLZ均具有活性。只有UGT1A4显示出针对dmCLZ的活性。 UGT1A1形成CLZ-N +-葡糖醛酸苷的Vmax / K M比UGT1A4高2.1倍(P <0.0001)。 UGT1A4是唯一可以确定CLZ-5-N-葡萄糖醛酸动力学的UGT。 UGT1A4 24Pro / 48Val变体显示形成CLZ-5-N-葡糖醛酸,CLZ-N-葡糖醛酸和dmCLZ的V max / KM分别高5.2、2.0和3.4倍(所有P <0.0001)与野生型UGT1A4 24Pro / 48Leu相比,分别具有-5-N +-葡萄糖醛酸。具有UGT1A1(* 28 / * 28)/ UGT1A4(* 1 / * 1)基因型和2.2-and基因型的HLM中CLZ-N +-葡萄糖醛酸化物形成率降低37%(P <0.05)与UGT1A1(* 1 / * 1)/ UGT1A4(* 3 / * 3)HLM相比,CLZ-5-N +-葡萄糖醛酸和CLZ-N-葡萄糖醛酸的形成增加1.8倍(两者均P <0.05) UGT1A1(* 1 / * 1)/ UGT1A4(* 1 / * 1)HLM。 UGT1A1 * 28等位基因是CLZ-N-葡糖醛酸苷形成的重要预测因子(P = 0.045); UGT1A4 * 3等位基因是CLZ-5-N +-葡萄糖醛酸和dmCLZ-葡萄糖醛酸形成的重要预测因子(P <0.0001)。结论:这些数据表明UGT1A1 * 28和UGT1A4 * 3等位基因显着影响了CLZ和dmCLZ代谢的个体差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号